The relationship between tumour necrosis factor (TNF)-α promoter and IL12B/IL-23R genes polymorphisms and the efficacy of anti-TNF-α therapy in psoriasis: A case-control study

British Journal of Dermatology

Volumn 169, Issue 4, 2013, Pages 819-829

  Gallo, E ^a   Cabaleiro, T ^a   Roman M ^a   Solano Lopez G ^a   Abad Santos, F ^a,b   Garcia Diez A ^a   Dauden E ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB;

ADULT; ARTICLE; BODY SURFACE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE; GENOTYPE; HAPLOTYPE; HUMAN; INTERLEUKIN 12P40 GENE; INTERLEUKIN 23 RECEPTOR GENE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PSORIASIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR NECROSIS FACTOR ALPHA GENE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CASE-CONTROL STUDIES; DERMATOLOGIC AGENTS; FEMALE; GENOTYPE; HUMANS; IMMUNOGLOBULIN G; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PSORIASIS; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-12; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84885417593     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12425     Document Type: Article

References (41)

1. Woolf RT, Smith CH,. How genetic variation affects patient response and outcome to therapy for psoriasis. Expert Rev Clin Immunol 2010; 6: 957-66.
2. Rácz E, Prens EP,. Molecular pathophysiology of psoriasis and molecular targets of antipsoriatic therapy. Expert Rev Mol Med. 2009; 11: e38.
3. Tak PP, Kalden JR,. Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther 2011; 13 (Suppl. 1): S5.
4. Wilson A, De Vries N, Pocioit F, et al,. An allelic polymorphism in the human tumor necrosis factor α promoter region is strongly associated with HLA A1 B8 and DR3 alleles. J Exp Med 1993; 177: 557-60.
5. Mugnier B, Balandraud N, Darque A, et al,. Polymorphism at position-308 of the tumor necrosis factor α gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 2003; 48: 1849-52.
6. Llanos C, Soto L, Sabugo F, et al,. Papel de los polimorfismos -238 y -308 del promotor del factor de necrosis tumoral alfa en la patogenia y respuesta a tratamiento anti-factor de necrosis tumoral alfa en artritisreumatoide. Rev Méd Chile 2005; 133: 1089-95.
7. Cargill M, Schrodi SJ, Chang M, et al,. A large scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007; 80: 273-90.
8. Guis S, Balandraud N, Bouvenot J, et al,. Influence of -308A/G polymorphism in the tumor necrosis factor α gene on etanercept treatment in rheumatoid arthritis. Arthritis Rheum 2007; 15: 1426-30.
9. Plenge RM, Criswell LA,. Genetic variants that predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis: current challenges and future directions. Curr Opin Rheumatol 2008; 20: 145-52.
10. Cuchacovich M, Soto L, Edwardes M, et al,. Tumour necrosis factor-α (TNF-α) -308 G/G promoter polymorphism and TNF-α levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. Scand J Rheumatol 2006; 35: 435-40.
11. Cuchacovich M, Ferreira L, Aliste M, et al,. Tumour necrosis factor-α (TNF-α) levels and influence of -308 TNF-α promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis. Scand J Rheumatol 2004; 33: 228-32.
12. Maxwell JR, Potter C, Hyrich KL, et al,. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet 2008; 17: 3532-8.
13. Fabris M, Di Poi E, Sacco S, et al,. [ TNF-α gene polymorphisms in rheumatoid arthritis patients treated with anti-TNF-α agents: preliminary results ]. Reumatismo 2002; 34: 19-26 (in Italian).
14. Cavaleiro J, Fonseca J, Sobral M, et al,. Polymorphism at position -238 of the tumor necrosis factor alpha and rheumatoid arthritis: prognosis and pharmacogenetics-interim analysis. Ann Rheum Dis 2004; 63 (Suppl. I): 177.
15. Seitz M, Wirthmüller U, Möller B, Villiger PM,. The -308 tumour necrosis factor-α gene polymorphism predicts therapeutic response to TNF-α blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology 2007; 46: 93-6.
16. O'Rielly DD, Roslin NM, Beyene J, et al,. TNF-alpha-308 G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis. Pharmacogenomics J 2009; 9: 161-7.
17. Oregón-Romero E, Vázquez-Del Mercado M, Ruiz-Quezada SL, et al,. Tumor necrosis factor alpha-308 and -238 polymorphisms in rheumatoid arthritis. Association with messenger RNA expression and sTNF-alpha. J Investig Med 2008; 56: 937-43.
18. Magalhães RF, Biral AC, Pancoto JA, et al,. Human leukocyte antigen (HLA) and single nucleotide polymorphisms (SNPs) tumor necrosis factor (TNF)-alpha -238 and -308 as genetic markers of susceptibility to psoriasis and severity of the disease in a long-term follow-up Brazilian study. Int J Dermatol 2010; 49: 1133-40.
19. Reich K, Hüffmeier U, König IR, et al,. TNF polymorphisms in psoriasis: association of psoriatic arthritis with the promoter polymorphism TNF*-857 independent of the PSORS1 risk allele. Arthritis Rheum 2007; 56: 2056-64.
20. Giardina E, Hüffmeier U, Ravindran J, et al,. Tumor necrosis factor promoter polymorphism TNF*-857 is a risk allele for psoriatic arthritis independent of the PSORS1 locus. Arthritis Rheum 2011; 63: 3801-6.
21. Kang SP, Lee KW, Yoo DH, et al,. The influence of a polymorphism at position -857 of the tumour necrosis factor α gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology 2005; 44: 547-52.
22. Date Y, Seki N, Kamizono S, et al,. Identification of a genetic risk factor for systemic juvenile rheumatoid arthritis in the 5′-flanking region of the TNFalpha gene and HLA genes. Arthritis Rheum 1999; 42: 2577-82.
23. Gallo E, Cabaleiro T, Román M, et al,. Study of genetic polymorphisms in the tumor necrosis factor α promoter region in Spanish patients with psoriasis. Actas Dermosifiliogr 2012; 103: 301-7.
24. Mascheretti S, Hampe J, Kühbacher T, et al,. Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. Pharmacogenomics J 2002; 2: 127-36.
25. Capon F, Di Meglio P, Szaub J, et al,. Sequence variants in the genes for the interlukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet 2007; 122: 201-6.
26. Nair RP, Stuart PE, Kullavanijaya P, et al,. Genetic evidence for involvement of the IL23 pathway in Thai psoriatics. Arch Dermatol Res 2010; 302: 139-43.
27. Smith RL, Warren RB, Eyre S, et al,. Polymorphisms in the IL-12β and IL-23R genes are associated with psoriasis of early onset in a U.K. cohort. J Invest Dermatol 2008; 158: 962-8.
28. Wu Y, Lu Z, Chen Y, et al,. Replication of association between interleukin-23 receptor (IL-23R) and its ligand (IL-12B) polymorphisms and psoriasis in the Chinese Han population. Hum Immunol 2010; 71: 1255-8.
29. Zheng HF, Zuo XB, Lu WS, et al,. Variants in MHC, LCE and IL12B have epistatic effects on psoriasis risk in Chinese population. J Dermatol Sci 2011; 61: 124-8.
30. Huffmeier U, Lascorz J, Bohm B, et al,. Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. J Invest Dermatol 2009; 129: 355-8.
31. Filer C, Ho P, Smith RL, et al,. Investigation of association of the Il12B and Il23R genes with psoriatic arthritis. Arthritis Rheum 2008; 58: 3705-9.
32. Farago B, Magyari L, Safrany E, et al,. Functional variants of interleukin-23 receptor gene confer risk for rheumatoid arthritis but not for systemic sclerosis. Ann Rheum Dis 2008; 67: 248-50.
33. Tejasvi T, Stuart PE, Chandran V, et al,. TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. J Invest Dermatol 2012; 132: 593-600.
34. Di Renzo L, Bianchi A, Saraceno R, et al,. -174G/C IL-6 gene promoter polymorphism predicts therapeutic response to TNF-α blockers. Pharmacogenet Genomics 2012; 22: 134-42.
35. Jamnitski A, Krieckaert CL, Nurmohamed MT, et al,. Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann Rheum Dis 2012; 71: 88-91.
36. Lecluse LL, Driessen RJ, Spuls PI, et al,. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol 2010; 146: 127-32.
37. Rothman KJ,. No adjustments are needed for multiple comparisons. Epidemiology 1990; 1: 43-6.
38. Savitz DA, Olshan AF,. Describing data requires no adjustment for multiple comparisons: a reply from Savitz and Olshan. Am J Epidemiol 1998; 147: 813-14.
39. Thompson JR,. Invited commentary: re: 'Multiple comparisons and related issues in the interpretation of epidemiologic data'. Am J Epidemiol 1998; 147: 801-6.
40. Perneger TV,. What's wrong with Bonferroni adjustments. BMJ 1998; 316: 1236-8.
41. Feise RJ,. Do multiple outcome measures require p-value adjustment? BMC Med Res Methodol 2002; 2: 8.